CEACAM5 and neoplasm: In all cases, pretargeted immuno-PET was able to detect very small tumour lesions after optimizing the TF2/IMP-288 molar dose ratio and the pretargeted delay for the anti-CEA bispecific antibody TF2 and 68Ga-labeled IMP288 bivalent hapten.